Maintenance asthma treatment with fluticasone/salmeterol combination via diskus

Effect on outcomes in inner-city children enrolled in TennCare

William T. Nguyen, Charles Stewart, Kimberley Fisher, Elizabeth Tolley, Dukhee Betty Lew, Timothy H. Self

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Although current national guidelines suggest combination inhaled corticosteroid/long-acting inhaled β 2-agonist as the preferred treatment in moderate and severe persistent asthma for children, trials aimed at reducing emergency department (ED) visits and hospitalizations in minority inner-city children have not been conducted with the combination product of fluticasone/salmeterol via Diskus (Advair). This study assessed the effect of fluticasone/salmeterol combination via Diskus therapy on hospitalizations and ED visits in children with asthma. We conducted a prospective 1-year study with an intervention group compared with a usual care control group. This study took place at an inner-city university-affiliated children's medical center allergy clinic. Inner-city patients with asthma aged 4-17 years with a history of frequent ED visits and hospitalizations for the 2 previous years were enrolled beginning in July 2001. A control group of inner-city asthmatic patients was identified via hospital medical records. Patients were prescribed fluticasone/salmeterol combination via Diskus (n = 39) for 1 year and were compared with a usual care control group (n = 39). Although the investigators did not intervene in the control patients, review of their records revealed that all control patients had inhaled corticosteroids prescribed during the intervention period. Outcome measures included ED visits and hospitalizations for 1 year after enrollment versus the mean for acute care visits for 2 years before enrollment in the study. The intervention group had a 20% reduction in ED visits, which was significant compared with the control group (p = 0.017); both groups had significant reductions in hospitalizations. The risk of experiencing an asthma exacerbation (ED visit or hospitalisation) was reduced by 33% in the intervention group compared with the control group (risk ratio, 0.67; 95% confidence interval, 0.49-0.90; p = 0.005). Our results suggest that fluticasone/salmeterol combination via Diskus is associated with a reduction in risk of acute exacerbations of asthma in inner-city children, including ED visits and hospitalizations.

Original languageEnglish (US)
Pages (from-to)129-134
Number of pages6
JournalAllergy and Asthma Proceedings
Volume26
Issue number2
StatePublished - Mar 1 2005

Fingerprint

Hospital Emergency Service
Hospitalization
Asthma
Maintenance
Control Groups
Therapeutics
Adrenal Cortex Hormones
Hospital Records
Risk Reduction Behavior
Salmeterol Xinafoate Drug Combination Fluticasone Propionate
Medical Records
Hypersensitivity
Odds Ratio
Research Personnel
Outcome Assessment (Health Care)
Guidelines
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Maintenance asthma treatment with fluticasone/salmeterol combination via diskus : Effect on outcomes in inner-city children enrolled in TennCare. / Nguyen, William T.; Stewart, Charles; Fisher, Kimberley; Tolley, Elizabeth; Lew, Dukhee Betty; Self, Timothy H.

In: Allergy and Asthma Proceedings, Vol. 26, No. 2, 01.03.2005, p. 129-134.

Research output: Contribution to journalArticle

Nguyen, William T. ; Stewart, Charles ; Fisher, Kimberley ; Tolley, Elizabeth ; Lew, Dukhee Betty ; Self, Timothy H. / Maintenance asthma treatment with fluticasone/salmeterol combination via diskus : Effect on outcomes in inner-city children enrolled in TennCare. In: Allergy and Asthma Proceedings. 2005 ; Vol. 26, No. 2. pp. 129-134.
@article{a4387267ac944ad399216302b18c1840,
title = "Maintenance asthma treatment with fluticasone/salmeterol combination via diskus: Effect on outcomes in inner-city children enrolled in TennCare",
abstract = "Although current national guidelines suggest combination inhaled corticosteroid/long-acting inhaled β 2-agonist as the preferred treatment in moderate and severe persistent asthma for children, trials aimed at reducing emergency department (ED) visits and hospitalizations in minority inner-city children have not been conducted with the combination product of fluticasone/salmeterol via Diskus (Advair). This study assessed the effect of fluticasone/salmeterol combination via Diskus therapy on hospitalizations and ED visits in children with asthma. We conducted a prospective 1-year study with an intervention group compared with a usual care control group. This study took place at an inner-city university-affiliated children's medical center allergy clinic. Inner-city patients with asthma aged 4-17 years with a history of frequent ED visits and hospitalizations for the 2 previous years were enrolled beginning in July 2001. A control group of inner-city asthmatic patients was identified via hospital medical records. Patients were prescribed fluticasone/salmeterol combination via Diskus (n = 39) for 1 year and were compared with a usual care control group (n = 39). Although the investigators did not intervene in the control patients, review of their records revealed that all control patients had inhaled corticosteroids prescribed during the intervention period. Outcome measures included ED visits and hospitalizations for 1 year after enrollment versus the mean for acute care visits for 2 years before enrollment in the study. The intervention group had a 20{\%} reduction in ED visits, which was significant compared with the control group (p = 0.017); both groups had significant reductions in hospitalizations. The risk of experiencing an asthma exacerbation (ED visit or hospitalisation) was reduced by 33{\%} in the intervention group compared with the control group (risk ratio, 0.67; 95{\%} confidence interval, 0.49-0.90; p = 0.005). Our results suggest that fluticasone/salmeterol combination via Diskus is associated with a reduction in risk of acute exacerbations of asthma in inner-city children, including ED visits and hospitalizations.",
author = "Nguyen, {William T.} and Charles Stewart and Kimberley Fisher and Elizabeth Tolley and Lew, {Dukhee Betty} and Self, {Timothy H.}",
year = "2005",
month = "3",
day = "1",
language = "English (US)",
volume = "26",
pages = "129--134",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Maintenance asthma treatment with fluticasone/salmeterol combination via diskus

T2 - Effect on outcomes in inner-city children enrolled in TennCare

AU - Nguyen, William T.

AU - Stewart, Charles

AU - Fisher, Kimberley

AU - Tolley, Elizabeth

AU - Lew, Dukhee Betty

AU - Self, Timothy H.

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Although current national guidelines suggest combination inhaled corticosteroid/long-acting inhaled β 2-agonist as the preferred treatment in moderate and severe persistent asthma for children, trials aimed at reducing emergency department (ED) visits and hospitalizations in minority inner-city children have not been conducted with the combination product of fluticasone/salmeterol via Diskus (Advair). This study assessed the effect of fluticasone/salmeterol combination via Diskus therapy on hospitalizations and ED visits in children with asthma. We conducted a prospective 1-year study with an intervention group compared with a usual care control group. This study took place at an inner-city university-affiliated children's medical center allergy clinic. Inner-city patients with asthma aged 4-17 years with a history of frequent ED visits and hospitalizations for the 2 previous years were enrolled beginning in July 2001. A control group of inner-city asthmatic patients was identified via hospital medical records. Patients were prescribed fluticasone/salmeterol combination via Diskus (n = 39) for 1 year and were compared with a usual care control group (n = 39). Although the investigators did not intervene in the control patients, review of their records revealed that all control patients had inhaled corticosteroids prescribed during the intervention period. Outcome measures included ED visits and hospitalizations for 1 year after enrollment versus the mean for acute care visits for 2 years before enrollment in the study. The intervention group had a 20% reduction in ED visits, which was significant compared with the control group (p = 0.017); both groups had significant reductions in hospitalizations. The risk of experiencing an asthma exacerbation (ED visit or hospitalisation) was reduced by 33% in the intervention group compared with the control group (risk ratio, 0.67; 95% confidence interval, 0.49-0.90; p = 0.005). Our results suggest that fluticasone/salmeterol combination via Diskus is associated with a reduction in risk of acute exacerbations of asthma in inner-city children, including ED visits and hospitalizations.

AB - Although current national guidelines suggest combination inhaled corticosteroid/long-acting inhaled β 2-agonist as the preferred treatment in moderate and severe persistent asthma for children, trials aimed at reducing emergency department (ED) visits and hospitalizations in minority inner-city children have not been conducted with the combination product of fluticasone/salmeterol via Diskus (Advair). This study assessed the effect of fluticasone/salmeterol combination via Diskus therapy on hospitalizations and ED visits in children with asthma. We conducted a prospective 1-year study with an intervention group compared with a usual care control group. This study took place at an inner-city university-affiliated children's medical center allergy clinic. Inner-city patients with asthma aged 4-17 years with a history of frequent ED visits and hospitalizations for the 2 previous years were enrolled beginning in July 2001. A control group of inner-city asthmatic patients was identified via hospital medical records. Patients were prescribed fluticasone/salmeterol combination via Diskus (n = 39) for 1 year and were compared with a usual care control group (n = 39). Although the investigators did not intervene in the control patients, review of their records revealed that all control patients had inhaled corticosteroids prescribed during the intervention period. Outcome measures included ED visits and hospitalizations for 1 year after enrollment versus the mean for acute care visits for 2 years before enrollment in the study. The intervention group had a 20% reduction in ED visits, which was significant compared with the control group (p = 0.017); both groups had significant reductions in hospitalizations. The risk of experiencing an asthma exacerbation (ED visit or hospitalisation) was reduced by 33% in the intervention group compared with the control group (risk ratio, 0.67; 95% confidence interval, 0.49-0.90; p = 0.005). Our results suggest that fluticasone/salmeterol combination via Diskus is associated with a reduction in risk of acute exacerbations of asthma in inner-city children, including ED visits and hospitalizations.

UR - http://www.scopus.com/inward/record.url?scp=20044369019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044369019&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 129

EP - 134

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 2

ER -